

Suboxone/Subutex – New York

**Prior Authorization Request Form** 

Please complete this <u>entire</u> form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form may contain multiple pages. Please complete all pages to avoid a delay in our decision. Allow at least 24 hours for review.

Section A – Member Inform	ation									
First Name:		Last Name:				Member ID:				
Address:										
City:	State:				ZIP Code:					
Phone:	DOB:				Allergies:					
Primary Insurance Information (	if any):									
Is the requested medication: <ul> <li>New or</li> <li>Continuation of Therapy? If continuation, list start date:</li> </ul>										
Is this patient currently hospitalized? <ul> <li>Yes</li> <li>No</li> <li>If recently discharged, list discharge date:</li> </ul>										
Section B - Provider Inform	nation									
First Name:			Last Name: M.D./D.O							
Address:			City:			State: ZIP code:				
Phone:	Phone: Fax:			NPI #: S			Specialty:			
Office Contact Name / Fax atter	ntion to:									
Section C - Medical Information Medication: Strength:										
Directions for use:						Quantity:				
Diagnosis (Please be specific & provide as much information as possible):       ICD-10							D-10 CODE:			
Is this member pregnant?   Yes No If yes, what is this member's due date?										
Section D – Previous Medic	cation Trials					_	6 6 H /			
Medication Name	Strength	Dire	ctions	ns Dates of Therap		, Reason for failure / discontinuation				
Section E – Additional info Please refer t	rmation and Ex to the patient's	planation of PDL at ww	of why prefer	rred medications wo ler.com for a list of p	uld not	t meet the	patient's needs:			
			manopromo			a anoma				



**Community Plan** 

Prior Authorization Request Form

Member First name:		Member Last name:	Member DOB:				
		Clinical and Drug Spe	ific Information				
			l is 12.6/2 mg (2 films of the 6/3/1.0mg). /4.2mg (2 tabs of the 8.6/2.1mg).				
		ALL REQUEST	S				
🗆 Yes 🗆 No	Does the patient have a Diagnostic and Statistical Manual, Fifth Edition, Text Revision (DSM-V-TR), diagnosis of opioid use disorder?						
□ Yes □ No	Is there a reason or special circumstance why the patient cannot use BOTH of the following: <ul> <li>Buprenorphine/naloxone sublingual film</li> <li>Buprenorphine/naloxone sublingual tablet</li> </ul> <li>If yes, list reason or special circumstance:</li>						
□ Yes □ No	Does the requested quantity exceed 24mg of buprenorphine daily or equivalent dosing of an alternative medication?						
CONTINUATION OF THERAPY							
□ Yes □ No	Has the patient been pre maintenance therapy?	scribed a buprenorphine	roduct for the purpose of opioid use disorder				

## Provider Signature: \_\_\_\_\_

Date:

**Confidentiality Notice:** This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.